share_log

Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $55

Benzinga Real-time News ·  Nov 9, 2022 07:38

Chardan Capital analyst Keay Nakae maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $65 to $55.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment